STALICLA
10.12.2020 19:02:13 CET | Business Wire | Press release
STALICLA SA , today announced first patient enrolled in its Phase 1b clinical trial with STP1, a first in class precision medicine for patients within the autism spectrum disorder (ASD) Phenotype 1 subgroup (ASD-Phen1), a novel biological subgroup identified by STALICLA’s proprietary discovery platform. STP1 is a novel combination of compounds: a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1, specifically targeting the biological dysregulations linked to ASD-Phen1.
Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders (NDDs) currently diagnosed based on core behavioral features, including persistent deficits in social communication and social interaction, restricted and repetitive patterns of behavior, interests, or activities. Significant impairment in daily functioning should also be present. Globally, ASD is highly prevalent and affects approximately 10 million patients in Europe and the United States and more throughout the world. There are no biological criteria for this diagnosis. ASD is characterized by high levels of clinical and genetic heterogeneity, supporting the existence of ASD biological subtypes requiring differential pharmacological treatment strategies.
By combining real-world patient data and its proprietary systems biology and AI-powered drug discovery platform called DEPI (Databased Endophenotyping Patient Identification), STALICLA is uncovering novel patterns of non-behavioral and biologically defined parameters amongst patients with ASD. STALICLA has already identified ASD Phenotype 1, a first subpopulation of patients with idiopathic ASD that can be identified by distinct multi-omics biomarkers. ASD Phenotype 1 is characterized by dysregulation of key intracellular pathways, transcription factors and immune factors. The most recent biomarker data related to ASD Phenotype 1 will be presented by STALICLA ahead of publication at the BRAIN Foundation Synchrony 2020 conference on December 12, 2020 (online).
“STALICLA is the first company developing precision medicine treatments for a biologically defined subgroup of patients with ASD. A diagnosis of autism must be integrated with other layers of data to capture biologically specific mechanisms, enabling the identification of precision drug candidates to improve on the outcome of clinical trials. STALICLA has built its DEPI drug discovery platform to achieve just this. By defining novel ASD phenotypes based on clinical signs and symptoms and not only on behaviors, STALICLA is creating a precision medicine approach to discovering and developing novel treatments for patients with ASD,” said Lynn Durham, M.Sc. Chief Executive Officer and founder of STALICLA.
“This Phase 1b study for STP1 marks the first time that a precision therapeutic will be investigated in patients with a non-monogenetic cause of ASD. While the trial progresses, STALICLA will continue to drive forward its proprietary and partnered programs to define additional ASD Phenotypes and advance a robust pipeline of therapeutic candidates for ASD and other NDDs,” said, Delphine Charvin, PhD, STALICLA’s Chief Scientific Officer.
“Despite the high prevalence of neurodevelopmental disorders in the U.S. and Europe, most NDDs are diagnosed and treated based on behavioral-based classification systems alone,” said Study Investigator, Craig Erickson, MD, Cincinnati Children’s Hospital Medical Center. “I look forward to investigating the potential of STP1 in the first clinically validated subpopulation of patients with idiopathic ASD.”
The double-blind, placebo-controlled, first-in-human study is being conducted at Cincinnati Children’s Hospital Medical Center in Cincinnati, Ohio. The primary objective of the trial is to evaluate the safety and tolerability of a two-week oral treatment with STP1 in adult patients who match the ASD-Phen1 clinical criteria. Two ascending dose cohorts of approximately 12 patients each will be enrolled. The study will also assess the pharmacokinetic and pharmacodynamic effects of STP1 and includes exploratory efficacy surrogate endpoints.
About ASD Phenotype 1
ASD Phenotype 1 (ASD-Phen1) is a subgroup of patients with autism spectrum disorder which has been identified by STALICLA’s platform and includes as many as 20% of the total ASD population with a non-monogenetic cause. ASD-Phen1 was first validated by an observational clinical trial conducted at the Greenwood Genetic Center (South Carolina, U.S.). ASD-Phen1 criteria were applied to a cohort of 313 patients with ASD. The study led to the identification of patients who matched the required clinical criteria and represented the first clinical validation of the ASD-Phen1 subgroup. Further biological characterization of ASD-Phen1 revealed a specific biological signature, or “fingerprint,” of the patient subgroup that was consistent with the signature proposed by STALICLA’s DEPI drug discovery platform.
About STP1
STALICLA’s investigational new drug, named STP1, is a first-in-class precision medicine being developed as part of the company’s proprietary pipeline for the treatment of ASD for patients within the Phenotype 1 subgroup (ASD-Phen1). STP1 is a novel combination of a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1. STP1 was identified as a potential match for ASD Phenotype 1 using the DEPI platform, addressing ASD-Phen1 biological dysfunctions and limiting the emergence of compensatory disease pathways. In addition, STP1 has shown a good safety profile in nonclinical toxicology studies. Taken individually, both compounds have also demonstrated good clinical safety and tolerability profiles over a broad range of doses and non-ASD indications.
About STALICLA
STALICLA is reframing neurodevelopmental disorders on the basis of novel insights into their biological underpinnings. By combining real-world patient data and a proprietary systems biology and AI-powered drug discovery platform called DEPI, STALICLA is uncovering novel patient subgroups, enabling targeted clinical development and fueling a rich pipeline of precision therapies. STALICLA has formed a global network of partnerships to bring the first precision medicine treatments to patients with NDDs as efficiently as possible with an initial focus on autism spectrum disorder (ASD). https://stalicla.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005723/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vena To Acquire Acterys, Creating a New Category of Enterprise Performance Management: Orchestrated Planning3.2.2026 17:00:00 CET | Press release
The acquisition unites finance foresight and IT innovation in the first Microsoft-native Orchestrated Planning environment, helping enterprises plan better and achieve more by turning strategy into aligned execution in real time. Vena, the only complete FP&A platform powered by agentic AI and purpose-built to amplify the Microsoft technology ecosystem, today announced it has entered into a definitive agreement to acquire Managility Pty Ltd, operating as Acterys (“Acterys”), the industry’s leading Power BI–based operational planning and app development platform, subject to customary closing conditions and regulatory approval. This acquisition unlocks a category-defining way for enterprises to combine planning, analytics, and application development within the Microsoft tools they already trust to run their business. By combining Vena’s Excel-native financial planning and analysis (FP&A) capabilities with Acterys’ proprietary Power BI write-back engine and unified analytics within Micros
Volante Technologies named a Leader in Gartner® Magic Quadrant™ for Banking Payment Hub Platforms3.2.2026 16:15:00 CET | Press release
Volante believes its solutions provide complete always-on payment processing support for banks and financial institutions across all tiers Volante Technologies, the global leader in Payments as a Service (PaaS), today announced its recognition as a Leader in the 2026 Gartner® Magic Quadrant™ for Banking Payment Hub Platforms, which evaluates vendors based on Ability to Execute and Completeness of Vision. In Volante’s view, Gartner positioned them as a Leader based on their capacity to support enterprise-scale payment processing in banks and financial institutions across multiple regions, deployment models, and operational environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203149834/en/ This graphic was published by Gartner, Inc. as part of a larger research document and should be evaluated in the context of the entire document. As the highest positioned provider in Ability to Execute, Volante believes its AI-pow
Toptal Ranked #1 Most Reliable Professional Services Company in America by Newsweek3.2.2026 16:00:00 CET | Press release
Toptal, the world’s largest fully remote workforce, has been ranked the #1 most reliable professional services company in America on the America’s Most Reliable Companies 2026 list by Newsweek and Statista. The list ranks top US companies based on trust, dependability, and consistent performance in their industry. In Newsweek’s ranking of 300 companies across all industries, Toptal took 10th place, right behind Bank of America and Oracle, which tied for 9th. As the most reliable professional services organization in America, Toptal, which ranked 11th in absolute rankings across all companies, placed well ahead of companies like Accenture (33), Deloitte (39), and Cognizant (66). The America’s Most Reliable Companies 2026 ranking is based on an independent survey of more than 80,000 evaluations submitted by 2,400 business decision-makers at America’s largest companies, including Apple, Dropbox, Johnson & Johnson, and UPS, making this recognition an especially meaningful indicator of prod
HTEC Research Reveals the Real AI Scaling Challenge: It’s Not the Technology3.2.2026 15:46:00 CET | Press release
Global executive survey finds AI momentum is real—but leadership alignment, capability gaps, and ROI clarity are slowing enterprise impact AI has moved from ambition to action. Every organization is deploying it. Yet for most enterprises, the real challenge is only just beginning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203951136/en/ HTEC, a global AI‑first provider of software and hardware design and engineering services, released Executive Summary: A Cross‑Industry View of the State of AI in 2025, a global research report capturing how senior executives are navigating the next phase of AI transformation—and why scaling value remains elusive. Today, HTEC, a global AI‑first provider of software and hardware design and engineering services, released Executive Summary: A Cross‑Industry View of the State of AI in 2025, a global research report that captures how senior executives are navigating the next phase of AI tra
Yubico Reveals 265% ROI and 99.99% Reduction in Risk of Exposure to Addressable Breach Risk Costs According to Total Economic Impact Study3.2.2026 15:00:00 CET | Press release
Effectiveness of Yubico’s technology: $5.3 million Net Present Value and $7.3 million in total benefits over three years, driven by 80% faster authentication and reduced help desk burden Yubico (NASDAQ STOCKHOLM: YUBICO), a modern cybersecurity company and creator of the most secure passkeys, today announced the results of a commissioned Total Economic Impact™ (TEI) of Yubico YubiKeys study conducted by Forrester Consulting. The study, comprised of interviews with global enterprises with over 5,000 employees, found that a composite organization based on interviewed customers achieved a 265% return on investment (ROI) and a net present value (NPV) of $5.3 million over three years by replacing traditional multi-factor authentication (MFA) and one-time passwords (OTPs) with phishing-resistant YubiKeys. In an era of high-quality deepfakes and generative AI-driven extortion, the study shows a critical shift in cybersecurity: traditional MFA is no longer sufficient to stop modern MFA-bypass
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom